| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,196 |
5,608 |
$587K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
6,741 |
5,780 |
$401K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
3,551 |
3,273 |
$332K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
3,204 |
2,689 |
$280K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
6,815 |
6,275 |
$268K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
2,175 |
1,970 |
$196K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
1,091 |
968 |
$102K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
3,073 |
2,857 |
$97K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
631 |
589 |
$22K |
| 92567 |
|
2,008 |
1,678 |
$21K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,893 |
1,673 |
$15K |
| 94760 |
|
6,879 |
5,339 |
$13K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
708 |
626 |
$11K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
396 |
356 |
$9K |
| 99058 |
|
454 |
388 |
$7K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
479 |
360 |
$6K |
| 87807 |
|
681 |
602 |
$5K |
| 99381 |
|
48 |
44 |
$4K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
151 |
94 |
$4K |
| G0447 |
Face-to-face behavioral counseling for obesity, 15 minutes |
159 |
150 |
$3K |
| 85018 |
|
1,926 |
1,728 |
$3K |
| 36416 |
|
2,538 |
2,234 |
$967.70 |
| 94664 |
|
92 |
78 |
$909.63 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
573 |
414 |
$871.05 |
| 90671 |
|
322 |
306 |
$677.99 |
| 90651 |
|
148 |
137 |
$639.01 |
| A7015 |
Aerosol mask, used with dme nebulizer |
573 |
409 |
$566.51 |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
26 |
12 |
$454.90 |
| 96127 |
|
73 |
64 |
$273.80 |
| 90700 |
|
657 |
611 |
$92.92 |
| 81002 |
|
51 |
47 |
$91.72 |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
12 |
12 |
$88.43 |
| 84030 |
|
16 |
14 |
$65.00 |
| 99000 |
|
2,223 |
1,940 |
$20.74 |
| J7633 |
Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 0.25 milligram |
85 |
56 |
$20.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
153 |
112 |
$13.49 |
| J7610 |
Albuterol, inhalation solution, compounded product, administered through dme, concentrated form, 1 mg |
182 |
153 |
$2.97 |
| 90686 |
|
1,745 |
1,597 |
$1.58 |
| A4250 |
Urine test or reagent strips or tablets (100 tablets or strips) |
14 |
13 |
$0.12 |
| 90670 |
|
1,395 |
1,319 |
$0.00 |
| 90633 |
|
778 |
741 |
$0.00 |
| 90713 |
|
86 |
82 |
$0.00 |
| 90685 |
|
188 |
175 |
$0.00 |
| 90734 |
|
102 |
99 |
$0.00 |
| 90710 |
|
78 |
75 |
$0.00 |
| 90715 |
|
59 |
48 |
$0.00 |
| 90707 |
|
40 |
38 |
$0.00 |
| 90648 |
|
27 |
26 |
$0.00 |
| 90744 |
|
535 |
514 |
$0.00 |
| 90680 |
|
852 |
809 |
$0.00 |
| 90698 |
|
1,129 |
1,067 |
$0.00 |
| 90716 |
|
40 |
37 |
$0.00 |
| 90619 |
|
64 |
60 |
$0.00 |
| 97802 |
|
19 |
19 |
$0.00 |